The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial.

Abstract

Herrero and colleagues show that in a phase III randomized trial in Guanacaste, Costa Rica, the use of a human papillomavirus type 16 (HPV16) and HPV18 ASO4-adjuvanted vaccine (Cervarix) resulted in complete efficacy against 12-month persistent HPV16 and HPV18 infections and partial protection against HPV31, 33, and 45 in HPV-naïve young women ages 18 to 25.

• Authors: F Xavier Bosch, Silvia de Sanjose, Xavier Castellsague
• Journal: Cancer discovery (Cancer Discov) Vol. 1 Issue 5 Pg. 377-80 (Oct 2011) ISSN: 2159-8290 [Electronic] United States
• PMID: 22586628 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Comment)
• Copyright: ©2011 AACR.

Chemical References

• Papillomavirus Vaccines

Topics

• Female
• Human papillomavirus 16 (immunology)
• Human papillomavirus 18 (immunology)
• Humans
• Papillomavirus Infections (prevention & control, virology)
• Papillomavirus Vaccines (therapeutic use)